BioSpace News Archive

The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that in anticipation of COVID-19 vaccines becoming available soon, the Company has procured factory capacity for production of over one billion, FDA-approved hypodermic needles and syringes that will be required for administration of vaccinations to the public on a global basis.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has closed a $50 million Licensing and Development Agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO)

USA dominates influential list of researchers recognized by their peers, but global landscape shifts as Chinese researchers capture a 12% share

va-Q-tec, a pioneer of highly efficient thermal containers and boxes for temperature-controlled logistics, announces the successful conclusion of a comprehensive agreement with one of the largest pharmaceutical manufacturers for the international distribution of a coronavirus vaccine.

Some patients with COVID-19 are at higher risk of neurological complications like bleeding in the brain and stroke, according to a study being presented at the annual meeting of the Radiological Society of North America.

Ra Medical Systems, Inc., a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces it will feature the Pharos excimer laser at the New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium 2020 Virtual Meeting being held November 21, 2020.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that it will be presenting two on-demand oral presentations as part of the 2020 Society for Neuro-Oncology Annual Meeting, which is being held virtually from November 19-21, 2020.

TwinStrand Biosciences announced it has entered into a worldwide non-exclusive agreement to sublicense two foundational patent families to Foundation Medicine and its affiliates relating to TwinStrand Duplex Sequencing™ error-correction technology.

Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea.

Shawn M. Leland, Founder of Elevation Oncology, Named Chief Executive Officer; Steve Elms, Managing Partner of Aisling Capital, to Remain Chair of Elevation Oncology Board of Directors